Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Mildred Iro, a Paediatric Research Fellow working with the Oxford Vaccine Group, won the Lorber Prize for the best paediatric publication of 2017 for her work on childhood encephalitis admissions.

The winning paper, published in Lancet in April 2017, examined trends in hospital admission rates for encephalitis in children over a 33-year period (1979-2011). The results show that while hospital admission rates for all instances of childhood encephalitis in England increased between 1995 and 2011, admissions for mumps encephalitis decreased by 98%, and for measles by 97%, after the introduction of the two-dose MMR vaccination schedule. Mildred’s study is the first to quantify the effect of the MMR vaccine on childhood measles and mumps encephalitis admissions in England. It is also the first to define the incidence of all-cause childhood encephalitis in England.

Mildred Iro joined Oxford University’s Department of Paediatrics in 2012; in 2013 she commenced her DPhil at the Oxford Vaccine Group. She has done most of her paediatric training in Southampton, where she is planning to return after the completion of her doctorate to take up the position of an NIHR Academic Clinical Lecturer in Child Health and Genomics.

The Lorber Prize is given annually by the Royal College of Paediatrics and Child Health. The award honours a pre-consultant grade medical practitioner working in the UK for the best scientific paper related to paediatrics.

 

Similar stories

Professor Matthew Snape named NIHR Senior Investigator

Awards & Appointments

Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.

Oxford University extends COVID-19 vaccine study to children

COVID-19 Research

The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.

World Health Organization experts provide guidance on use of the Oxford vaccine

COVID-19 Research

WHO SAGE says Oxford's coronavirus vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group.

Oxford leads first trial investigating dosing with alternating vaccines

COVID-19 Research

The Oxford Vaccine Group is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.

Oxford vaccine stimulates broad antibody and T cell functions

COVID-19 Publication Research

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.